drugset / Trial / NCT00002236

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236 ↗

Completed 32 enrolled Pharmacia and Upjohn
Open-labelTreatment

Summary

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Delavirdine Small molecule — —
Subject INDINAVIR ANHYDROUS Other / unclassified — —
Subject Zidovudine Small molecule — —